Sunshine Biopharma Inc. - SBFM STOCK NEWS

Sunshine Biopharma (SBFM) announced progress in its COVID-19 study at the University of Georgia, focusing on two protease inhibitors aimed at preventing illness in transgenic mice exposed to SARS-CoV-2. Successful results may lead to FDA testing in human patients. The company is also developing Adva-27a, an anticancer drug effective against multidrug-resistant cancer cells, with clinical trials planned at McGill University. The ongoing projects highlight Sunshine Biopharma's commitment to advancing innovative treatment options amidst the COVID-19 pandemic.

Sunshine Biopharma (SBFM) announced the elucidation of the mechanism of action of their anticancer drug candidate, Adva-27a. Notably, Adva-27a evades P-glycoprotein, a key player in multidrug resistance in over 50% of cancer cases, and inhibits Topoisomerase II, allowing it to effectively destroy both drug-sensitive and drug-resistant cancer cells. Additionally, the company is developing SBFM-PL4, a potential oral treatment for COVID-19, in collaboration with the University of Georgia. Clinical trials for Adva-27a in pancreatic cancer are planned at McGill University's Jewish General Hospital.

Sunshine Biopharma (SBFM) has eliminated $250,000 in variable rate convertible debt, enhancing its financial standing. The necessary debt elimination paves the way for a re-application to uplist to the OTCQB in October 2021, after a prior rejection due to outstanding loans. CFO Camille Sebaaly emphasized the importance of protecting shareholders from dilution. With funding from RB Capital Partners, SBFM aims to remove all harmful debts, thus improving its balance sheet. The company continues to develop potential COVID-19 treatments and an anti-cancer compound, Adva-27a.

Sunshine Biopharma (SBFM) reported its Q1 2021 financials, showing Cash & Cash Equivalents of $1,796,596 as of March 31, 2021. Notable developments include a Notice of Allowance from the Canadian Intellectual Property Office for a new patent on Adva-27a, extending protection until 2033, and an exclusive licensing agreement with the University of Georgia for two Anti-Coronavirus compounds. The company launched a new eCommerce site selling over 20 nutritional products, all manufactured in Canada under GMP standards.

Sunshine Biopharma (SBFM) has filed a nonprovisional PCT patent application for its COVID-19 treatment, enhancing its intellectual property rights. This builds on a provisional application from May 2020, now extending coverage to include the Papain-Like Coronavirus protease (PLpro), crucial for viral replication and immune suppression. Collaborating with the University of Georgia, Sunshine is evaluating two PLpro inhibitors in hACE2-transgenic mice, aiming for efficacy against COVID-19 variants. The company also continues developing Adva-27a, an anticancer drug effective against multidrug-resistant cancers.

Sunshine Biopharma (SBFM) announced an additional $500,000 investment from RB Capital to support its Coronavirus drug development program. This funding will also facilitate research on the anti-cancer drug Adva-27a. The company is advancing its COVID-19 treatment, SBFM-PL4, alongside two compounds licensed from the University of Georgia, with promising initial results seen in mice studies. Sunshine Biopharma aims to expedite the drug development process and potentially seek FDA authorization for human trials.

Sunshine Biopharma (SBFM) has successfully completed a Maximum Tolerated Dose (MTD) study in mice for its COVID-19 treatment, demonstrating favorable results within the optimum range for human use. This antiviral drug, targeting PLpro, aims to inhibit SARS-CoV-2 replication. Following these results, Sunshine Biopharma plans to conduct efficacy studies in hACE2-transgenic mice. Additionally, they are developing an anticancer compound, Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells, with clinical trials planned at McGill University.

Sunshine Biopharma (SBFM) has secured $2,054,000 in financing, exceeding the initially announced $2,000,000 from RB Capital Partners. This funding, convertible at $0.43 per share, will support the development of its Coronavirus treatment and the anticancer drug Adva-27a, targeting pancreatic cancer. The company is conducting studies in collaboration with the University of Georgia to assess the efficacy of its antiviral compounds in transgenic mice. Clinical trials for Adva-27a are planned at McGill University’s Jewish General Hospital.

Sunshine Biopharma (SBFM) announced a 'Notice of Allowance' from the European Patent Office for a new patent on its anticancer compound, Adva-27a, extending its European protection until 2033. This follows a similar patent granted in the U.S. in 2019. Sunshine Biopharma is the sole owner of Adva-27a's intellectual property. The compound shows promising results against multidrug-resistant cancers, with upcoming clinical trials planned at McGill University. The company is also developing antiviral treatments for COVID-19, aiming to advance multiple compounds for clinical testing.